Bo Hyun Kim1,2, Young-Suk Lim2,3, Eun-Yang Kim4, Hyun-Joo Kong4, Young-Joo Won4, Seungbong Han5, Sohee Park6, Jae Seok Hwang2,7. 1. Center for Liver Cancer, National Cancer Center, Goyang, Republic of Korea. 2. Korean Liver Cancer Association, Seoul, Republic of Korea. 3. Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. 4. Korea Central Cancer Registry, Division of Cancer Registration and Surveillance, National Cancer Center, Goyang, Republic of Korea. 5. Department of Applied Statistics, Gachon University, Seongnam, Republic of Korea. 6. Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea. 7. Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea.
Abstract
BACKGROUND AND AIM: Over the past decade, the management of hepatocellular carcinoma (HCC) and viral hepatitis has been improved. We explored survival trends and factors affecting survival of HCC in a hepatitis B virus (HBV)-endemic population. METHODS: From 31 521 and 38 167 HCC registrants to the population-based national cancer registry in Korea, an HBV-endemic country, in the period of 2003-2005 and 2008-2010, we randomly sampled cohorts of 4515 and 4582 patients, respectively, for the investigation of clinical characteristics and survival. RESULTS: Compared with Cohort 2003-2005, Cohort 2008-2010 had significantly better liver function (Child-Turcotte-Pugh class A, 64.2% vs 71.6%; P < 0.001) and had more advanced tumor stages (Barcelona Clinic Liver Cancer stage B-D, 45.8% vs 50.4%; P < 0.001). HBV was the predominant cause of HCC in both cohorts (62.5% vs 62.2%; P = 0.70). Cohort 2008-2010 had significantly better overall survival than Cohort 2003-2005 by age-adjusted univariate, multivariable, and propensity score-matched analyses (median survival time, 17.2 vs 28.4 months; P < 0.001). In a subcohort analysis, a consistently significant inter-cohort improvement in survival was observed only in patients with HBV-related HCC (median survival, 16.1 vs 30.4 months; P < 0.001). The annual number of patients with HCC receiving oral antiviral agents for HBV precipitously increased from 93 in 2005 to 28 520 in 2010 in the country. CONCLUSIONS: The consistent improvement in survival of patients with HCC was confined to HBV-related HCC subcohort over the last decade in an HBV-endemic population. The survival improvement coincided with the exponential use of oral antiviral agents for HBV in the patients.
BACKGROUND AND AIM: Over the past decade, the management of hepatocellular carcinoma (HCC) and viral hepatitis has been improved. We explored survival trends and factors affecting survival of HCC in a hepatitis B virus (HBV)-endemic population. METHODS: From 31 521 and 38 167 HCC registrants to the population-based national cancer registry in Korea, an HBV-endemic country, in the period of 2003-2005 and 2008-2010, we randomly sampled cohorts of 4515 and 4582 patients, respectively, for the investigation of clinical characteristics and survival. RESULTS: Compared with Cohort 2003-2005, Cohort 2008-2010 had significantly better liver function (Child-Turcotte-Pugh class A, 64.2% vs 71.6%; P < 0.001) and had more advanced tumor stages (Barcelona Clinic Liver Cancer stage B-D, 45.8% vs 50.4%; P < 0.001). HBV was the predominant cause of HCC in both cohorts (62.5% vs 62.2%; P = 0.70). Cohort 2008-2010 had significantly better overall survival than Cohort 2003-2005 by age-adjusted univariate, multivariable, and propensity score-matched analyses (median survival time, 17.2 vs 28.4 months; P < 0.001). In a subcohort analysis, a consistently significant inter-cohort improvement in survival was observed only in patients with HBV-related HCC (median survival, 16.1 vs 30.4 months; P < 0.001). The annual number of patients with HCC receiving oral antiviral agents for HBV precipitously increased from 93 in 2005 to 28 520 in 2010 in the country. CONCLUSIONS: The consistent improvement in survival of patients with HCC was confined to HBV-related HCC subcohort over the last decade in an HBV-endemic population. The survival improvement coincided with the exponential use of oral antiviral agents for HBV in the patients.
Authors: Jeong Hee Yoon; Jeong Min Lee; Dong Ho Lee; Ijin Joo; Ju Hyun Jeon; Su Joa Ahn; Seung-Taek Kim; Eun Ju Cho; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon Journal: Liver Cancer Date: 2020-08-06 Impact factor: 11.740
Authors: Sang Min Yoon; Baek-Yeol Ryoo; So Jung Lee; Jong Hoon Kim; Ji Hoon Shin; Ji Hyun An; Han Chu Lee; Young-Suk Lim Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777
Authors: Won Young Jang; Woo Jin Chung; Byoung Kuk Jang; Jae Seok Hwang; Heon Ju Lee; Moon Joo Hwang; Young Oh Kweon; Won Young Tak; Soo Young Park; Su Hyun Lee; Chang Hyeong Lee; Byung Seok Kim; Si Hye Kim; Jeong Ill Suh; Jun Gi Park Journal: J Korean Med Sci Date: 2020-07-27 Impact factor: 2.153
Authors: Han Ah Lee; Young-Sun Lee; Beom Kyung Kim; Young Kul Jung; Seung Up Kim; Jun Yong Park; Ji Hoon Kim; Hyunggin An; Do Young Kim; Hyung Joon Yim; Sang Hoon Ahn; Jong Eun Yeon; Kwan Soo Byun; Kwang-Hyub Han; Soon Ho Um; Yeon Seok Seo Journal: Gut Liver Date: 2021-05-15 Impact factor: 4.519